EMA confirmed evidence does not support that HPV vaccines cause CRPS or POTS… but the Nordic Cochrane Center said their report is flawed…
The European Medicines Agency (EMA) started a review of HPV vaccines to further clarify aspects of their safety profile.
The review looked at available data with a focus on rare reports of two conditions:
complex regional pain syndrome (CRPS)
a chronic pain condition affecting the limbs,
postural orthostatic tachycardia syndrome (POTS)
a condition where the heart rate increases abnormally after sitting or standing up, causing symptoms such as dizziness and fainting, as well as headache, chest pain and weakness.
In its review the agency’s Pharmacovigilance Risk Assessment Committee(PRAC) considered the latest scientific knowledge, including any research that could help clarify the frequency of CRPS and POTS following vaccination or identify any causal link. Based on this review, the Committee decided whether to recommend any changes to product information to better inform patients and healthcare professionals.
EMA to further clarify safety profile of human papillomavirus (HPV) vaccines, ema press release, 13/07/2015.
More the opposite: DES-exposure in utero led to increased rate of miscarriage and preterm birth
Oestrogen supplementation, mainly diethylstilbestrol, for preventing miscarriages and other adverse pregnancy outcomes
Laboratory evidence in the 1940s demonstrated a positive role of placental hormones in the continuation of pregnancy. It was suggested that diethylstilbestrol (DES) was the oestrogen of choice for prevention of miscarriages. Observational studies were carried out with apparently positive results, on which clinical practice was based. This led to a worldwide usage of diethylstilbestrol despite controlled studies with contrary findings.
To determine the effects of antenatal administration of oestrogens, mainly diethylstilbestrol, on high risk and unselected pregnancy as regards miscarriages and other outcomes.
We searched the Pregnancy and Childbirth Group Specialised Register of controlled trials in November 2002.
Randomised and quasi-randomised trials were included.
DATA COLLECTION AND ANALYSIS:
Both reviewers extracted data from the studies identified that met the selection criteria, and the data were analysed using the RevMan software.
REVIEWER’S CONCLUSIONS: There was no benefit with the use of diethylstilbestrol in preventing miscarriages. Both short and long-term adverse outcomes in exposed offsprings were demonstration of the harm that this intervention caused women and their offspring during its usage.
NCBI, Oestrogen supplementation, mainly diethylstilbestrol, for preventing miscarriages and other adverse pregnancy outcomes, PMID: 12918007, 2003;(3):CD004353.